Literature DB >> 26434819

Tumor-Suppression Mechanisms of Protein Tyrosine Phosphatase O and Clinical Applications.

Man-Man Kang1, Shun-Lin Shan, Xu-Yang Wen, Hu-Sheng Shan, Zheng-Jun Wang.   

Abstract

Tyrosine phosphorylation plays an important role in regulating human physiological and pathological processes. Functional stabilization of tyrosine phosphorylation largely contributes to the balanced, coordinated regulation of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Research has revealed PTPs play an important suppressive role in carcinogenesis and progression by reversing oncoprotein functions. Receptor-type protein tyrosine phosphatase O (PTPRO) as one member of the PTPs family has also been identified to have some roles in tumor development. Some reports have shown PTPRO over-expression in tumors can not only inhibit the frequency of tumor cell division and induce tumor cell death, but also suppress migration. However, the tumor-suppression mechanisms are very complex and understanding is incomplete, which in some degree blocks the further development of PTPRO. Hence, in order to resolve this problem, we here have summarized research findings to draw meaningful conclusions. We found tumor-suppression mechanisms of PTPRO to be diverse, such as controlling G0/G1 of the tumor cell proliferation cycle, inhibiting substrate phosphorylation, down-regulating transcription activators and other activities. In clinical anticancer efforts, expression level of PTPRO in tumors can not only serve as a biomarker to monitor the prognosis of patients, but act as an epigenetic biomarker for noninvasive diagnosis. In addition, the re-activation of PTPRO in tumor tissues, not only can induce tumor volume reduction, but also enhance the susceptibility to chemotherapy drugs. So, we can propose that these research findings of PTPRO will not only support new study ideas and directions for other tumor- suppressors, importantly, but also supply a theoretical basis for researching new molecular targeting agents in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26434819     DOI: 10.7314/apjcp.2015.16.15.6215

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  2 in total

1.  PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.

Authors:  Xuben Hou; Jintong Du; Hao Fang
Journal:  J Cancer       Date:  2021-10-30       Impact factor: 4.207

2.  PTPRO-related CD8+ T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer.

Authors:  Hongmei Dong; Chaoyu Xie; Zhimeng Yao; Ruijun Zhao; Yusheng Lin; Yichen Luo; Shuanglong Chen; Yanfang Qin; Yexi Chen; Hao Zhang
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.